文献速递MDS 与骨髓增殖性肿瘤

伴中性粒细胞增多的MDS/MPN的特征、主要治疗与生存:一项基于人群的研究

Characteristics, primary treatment, and survival of MDS/MPN with neutrophilia: a population-based study.
PubMed 文献 · Blood Adv · 2023-01-01

该研究分析了2001至2019年间荷兰癌症登记处登记的347例成人伴中性粒细胞增多的MDS/MPN患者,描述了细胞遗传学与分子突变特征,并通过多因素Cox回归发现仅年龄、血红蛋白水平和异基因造血干细胞移植与总生存相关。作者据此提出,适合移植的患者应尽可能接受异基因移植。

要点

  • 伴中性粒细胞增多的MDS/MPN患者中,细胞遗传学异常仅见于年龄>65岁者,其中8号染色体三体最常见。
  • 检出16种不同分子突变,ASXL1最常见(22%),部分患者(16/101)携带多达3种不同突变。
  • 多因素Cox回归显示仅年龄(>65岁,HR 1.85;P=0.001)、血红蛋白水平和异基因造血干细胞移植(HR 0.51;P=0.039)与总生存相关。

核心结论

  • 作者提出,所有适合异基因造血干细胞移植的患者应尽可能接受异基因移植。
  • 作者认为必须努力改善不适合异基因造血干细胞移植患者的结局,这需要国际协作开展前瞻性干预研究。

研究设计与样本

  • 基于人群的队列研究,分析2001至2019年间荷兰癌症登记处登记的347例成人伴中性粒细胞增多的MDS/MPN患者。

主要发现

  • 细胞遗传学异常仅见于年龄>65岁患者,8号染色体三体为最常见异常。
  • 检出16种不同分子突变,ASXL1最常见(22%),部分患者(16/101)携带多达3种不同突变。
  • 多因素Cox回归中,仅年龄(>65岁;HR 1.85;P=0.001)、血红蛋白水平和异基因造血干细胞移植(HR 0.51;P=0.039)与总生存相关。

临床怎么用

  • 作者提出,所有适合异基因造血干细胞移植的患者应尽可能接受异基因移植。
  • 原文未据此给出其他治疗推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Myelodysplastic and myeloproliferative neoplasms (MDS/MPN) with neutrophilia, until recently called atypical chronic myeloid leukemia (aCML), being part of the MDS/MPN is a very rare disease with poor prognosis. Although emerging data reveal its cytogenetic and molecular profile, integrated survival and treatment data remain scarce. We analyzed a cohort of 347 adult patients diagnosed with MDS/MPN with neutrophilia, registered in the Netherlands Cancer Registry between 2001 and 2019. Our demographic baseline data align with other cohorts. We observed cytogenetic aberrations exclusively in patients aged >65 years, with trisomy 8 being the most common abnormality. We identified 16 distinct molecular mutations, with some patients (16/101) harboring up to 3 different mutations; ASXL1 being the most frequent one (22%). In a multivariable Cox regression analysis, only age, hemoglobin level and allogeneic hematopoietic stem cell transplant (alloHSCT) were associated with overall survival (aged >65 years; hazard ratio [HR] 1.85; P = .001 and alloHSCT HR, 0.51; P = .039). Because no other treatment modality seemed to affect survival and might cause toxicity, we propose that all patients eligible for alloHSCT should, whenever possible, receive an allogeneic transplant. It is imperative that we strive to improve outcomes for patients who are not eligible for alloHSCT. Tackling this challenge requires international collaborative efforts to conduct prospective intervention studies.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Klein SK, Huls GA, Visser O, et al. Characteristics, primary treatment, and survival of MDS/MPN with neutrophilia: a population-based study. Blood Adv. 2023. PMID: 37934881. doi:10.1182/bloodadvances.2023011181

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。